Billiontoone (NASDAQ:BLLN) Insider Sells $1,000,000.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $125.00, for a total value of $1,000,000.00. Following the sale, the insider directly owned 204,000 shares in the company, valued at $25,500,000. This trade represents a 3.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total value of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total value of $785,760.00.

Billiontoone Stock Performance

Shares of Billiontoone stock opened at $129.88 on Thursday. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70. The firm’s 50 day moving average is $103.33 and its two-hundred day moving average is $89.66. The firm has a market capitalization of $5.97 billion and a P/E ratio of 236.15.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. During the same quarter in the prior year, the firm posted ($0.39) EPS. The firm’s quarterly revenue was up 83.8% compared to the same quarter last year. Research analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. BTIG Research decreased their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Guggenheim began coverage on Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 target price for the company. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. raised their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BLLN. Rossby Financial LCC purchased a new stake in shares of Billiontoone in the fourth quarter valued at about $25,000. Wells Fargo & Company MN purchased a new position in shares of Billiontoone during the fourth quarter worth about $76,000. Smartleaf Asset Management LLC purchased a new position in shares of Billiontoone during the fourth quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone in the 4th quarter valued at about $82,000. Finally, Renaissance Capital LLC purchased a new stake in Billiontoone during the 4th quarter valued at approximately $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.